Doctor raises GLP 1 long term side effects as evidence on lasting gut symptoms stays thin

Physician Joseph Varon warned in a televised interview that GLP 1 long term side effects may include gut problems that persist after patients stop the drugs. His warning drew on cases from his own practice, not on published data. Varon is president and chief medical officer of the Independent Medical Alliance. He spoke to The National News Desk in an interview that CBS12 published on 29 October. The station's own write up said the interview did not show that the drugs caused the symptoms he described.

Claims of GLP 1 diarrhea after stopping

Varon said the problem he sees most often is in the gut. He told the program he has seen "a lot of long-term complications" in people who took a GLP 1 drug, even after they quit. He described patients who must rush to the bathroom with diarrhea after almost any meal. He said some of them had stopped the medicines two or three years earlier. He added that gastroenterologists he knows have told him they do not know what to do with these patients, and that they now give them other drugs to control the symptoms. "These medications carry some very serious risks," Varon said. The interview gave no count of affected patients and no case details.

Diarrhea, nausea, vomiting and constipation are known side effects of GLP 1 drugs, the CBS12 report noted. What has not been established is GLP 1 diarrhea after stopping, years after the last dose. The report said the interview did not show that the drugs caused the symptoms Varon described, and that evidence of gut problems lasting years after treatment remains limited. It added that infections, other digestive diseases and underlying health problems can cause the same symptoms. A doctor seeing such a patient would therefore look for other causes before blaming a drug taken years ago. Accounts from one practice can raise a question for researchers, but they cannot show how often a problem occurs or what caused it.

What the GLP 1 thyroid cancer warning says

Varon also pointed to animal research. "We know, for example, that in animal models there is an increase in the type of thyroid cancer that you can see," he said. Some GLP 1 drugs carry a boxed warning from the US Food and Drug Administration about thyroid C cell tumors seen in rodents, according to the report. A boxed warning is the most prominent safety alert on a US drug label. The drugs are generally not to be used by people with a personal or family history of medullary thyroid carcinoma. The same applies to people with multiple endocrine neoplasia syndrome type 2, an inherited condition linked to that cancer.

The report said the interview did not show that the drugs caused the symptoms Varon described, and that evidence of gut problems lasting years after treatment remains limited.

It remains unknown whether the rodent findings mean a higher risk of medullary thyroid carcinoma in people, the report said. That gap is the point Varon pressed. He argued that the drugs have not been in wide use for weight loss long enough to yield decades of safety data. "What we don't know is the safety data from decades of these medications," he said. The thyroid signal is not the only label question for the drug class. In Europe, a safety committee has added a rare eye condition to semaglutide warnings. Patients who worry about GLP 1 long term side effects can ask a doctor how their own medical history bears on the label warnings.

Benefits Varon does not dispute

Varon did not argue against the drugs. "They are very powerful medications," he said. "I don't dismiss their benefits." He explained that GLP 1 drugs mimic gut hormones that signal the brain and help control appetite, fullness and blood sugar. He said semaglutide, the active ingredient in Ozempic and Wegovy, can bring about 15% weight loss, and that some other agents can reach about 20%. Those figures are his summary, not a trial readout. The report noted that trial results vary with the drug, the dose, how long treatment lasts and who takes part. Readers comparing such numbers can use our guide to reading weight loss trial headlines.

He set those benefits against the risks of obesity itself. "We know that obesity increases the chance of having cancer in 13 different types of cancers," Varon said. The report said the Centers for Disease Control and Prevention links excess body weight to at least 13 cancer types, including colorectal, kidney, liver and endometrial cancer. Varon also estimated that about 13% of Americans had obesity several decades ago, against more than 40% in recent years. That estimate was his own, and Peptide Zone did not check it against national survey data. He argued that medicine has become good at treating obesity and now needs to get better at preventing it.

Weight regain after GLP 1 and muscle loss

The interview also touched on what happens when treatment ends. Clinical studies have shown that many people regain a large share of the weight they lost after stopping, although the amount varies, the report said. That raises the question of whether some patients need long term treatment to keep their results. Weight regain after GLP 1 treatment is a separate issue from the lasting gut symptoms Varon described. One concern is about what happens when people stop too soon. The other is about what stopping may leave behind, and it remains unproven. Both belong in the wider debate over GLP 1 long term side effects. Varon said keeping weight off usually requires steady attention to diet and physical activity.

Varon also warned that weight loss is not only fat. "You are also losing muscle weight," he said. The report noted that loss of lean mass can happen with any large weight reduction, whether it comes from medicine, diet or other methods. It said enough protein and suitable resistance exercise can help preserve muscle. How much muscle loss on GLP 1 drugs a person has may depend partly on how they eat and train while appetite is low. For gut side effects during treatment, Varon said his team tells patients to avoid big meals, eat smaller ones, limit very fatty foods and stay hydrated. Other remedies are being tested, including a Phase 3 trial of a drug for GLP 1 related vomiting.

Conclusion

Varon's warning adds a physician's account to the debate over GLP 1 long term side effects, but it rests on patients from his practice rather than published data. The thyroid warning comes from rodent studies, and its meaning for people is still unknown. Lasting diarrhea after stopping has not been shown to be caused by the drugs. Controlled long term studies would be needed to settle both questions. People with persistent symptoms should see a doctor, who can look for other causes. This report gives research context and is not medical advice.